Non-HDL Cholesterol and Menopause: Why Your Value Shifts

Non-HDL cholesterol is never drawn separately. The laboratory takes your total cholesterol and removes your HDL from it. What is left is the cholesterol locked inside the particles that carry a molecule of apolipoprotein B: LDL, IDL, VLDL, the remnants of fat digestion and Lp(a). Every one of them able to leave cholesterol behind in an artery wall.

Because this is a subtraction, your HDL determines the outcome just as much as your total does. That is exactly where the difference between women and men sits. Oestrogen sustains HDL production, so women in their reproductive years carry on average a higher HDL than men of the same age. At an identical total cholesterol, their non-HDL therefore comes out lower.

Two reports with a total cholesterol of 6.0 mmol/l can consequently mean something quite different. With an HDL of 1.9 mmol/l, 4.1 mmol/l of non-HDL remains; with an HDL of 1.1 mmol/l it is 4.9 mmol/l. The same total, and almost a whole millimole of difference in the burden that actually matters.

This number therefore resolves a misunderstanding that catches women more often than men. A raised total cholesterol can, alongside a high HDL, consist largely of protective cholesterol. The total on its own cannot separate the two; non-HDL can.

Non-HDL measures the cargo, not the number of particles. Each atherogenic particle carries exactly one apoB molecule, so ApoB counts the particles themselves and is the purer measure wherever the two figures diverge. Usually they agree, and across menopause they climb together. Non-HDL is the version that appears free of charge on every lipid panel.

It is also a derived value that cannot break. No estimate is involved and no fasting is required. The calculated LDL on the same report is more fragile, because it usually comes out of a formula that weighs in your triglycerides, and that estimate becomes unusable once triglycerides exceed roughly 4.5 mmol/l. Precisely in the situations that belong to women, such as the combined pill, a pregnancy, or oestrogen in tablet form, triglycerides rise. Non-HDL is then the sturdiest figure on the report.

A woman in her early fifties eats as she has always eaten and moves as she has always moved, and still watches her cholesterol values climb. That is the question asked most often about this blood value, and the answer is more matter-of-fact than it feels: the lipid profile shifts of its own accord across menopause.

Up to that point you hold an advantage. Oestradiol keeps HDL high and LDL relatively low, so non-HDL and ApoB sit more favourably in women than in men of the same age for years on end. Cardiovascular disease reaches women on average about a decade later. That advantage is often read as invulnerability, but it is a postponement rather than an exemption: cardiovascular disease remains one of the leading causes of death in women as well.

What happens during the transition years is well described. As oestradiol falls, total cholesterol, LDL, ApoB and therefore non-HDL all rise. The steepest shift falls in the year around your final period; before and after that it proceeds more gradually. At the same time fat distribution moves towards the abdomen and insulin sensitivity declines, which pushes triglycerides and VLDL particles up. All of those are counted inside non-HDL. The number thus climbs along two routes at once, while you have changed nothing.

Hormones you receive from outside do something to it too, and the route of administration matters. Oestrogen you swallow passes through the liver first and alters lipoprotein production there; oestrogen through the skin largely bypasses that first pass.

Hormone therapy is prescribed for menopausal complaints and not for your cholesterol. That the lipid profile moves along with it is a by-product, and it is no argument for starting or stopping a treatment on your own. That weighing-up belongs with your doctor, together with you.

Then the comparison almost everyone makes at home: your number next to your partner's. It does not hold up, and it fails in both directions. SCORE2, the European risk model that has estimated 10-year cardiovascular risk since 2021, works from age, sex, smoking, systolic blood pressure and non-HDL cholesterol, and uses separate risk functions for women and men. The same 3.4 mmol/l therefore represents a different absolute risk in a woman of 55 than in a man of 55.

The targets themselves, by contrast, are not split by sex. They belong to your risk category: below 2.2 mmol/l at very high risk, below 2.6 at high risk and below 3.4 at moderate risk, each one 0.8 mmol/l above the corresponding LDL target. A lower number than your partner's therefore says nothing in itself about your own goal, and an identical number says nothing either. You are each measured against your own profile.

That makes the 3.3 mmol/l on your report the most misread figure on the whole lipid panel. It describes what is usual in the population, not what is desirable for you. For one woman 3.3 is perfectly fine, for another it sits clearly above her goal, while the report shows exactly the same thing in both cases and flags nothing as abnormal. Which category applies to you follows from your age, blood pressure, smoking, glucose, family history and any previous cardiovascular disease, and that is your doctor's judgement.

Finally, physiological does not mean unimportant. That the rise belongs to menopause makes the particle burden behind it no less real. It makes this life stage a logical moment to look at your LDL, your blood pressure and your glucose together, rather than judging a single number.

Non-HDL appears on every lipid panel automatically, because it is nothing more than two values already printed there, subtracted from one another. Fasting is unnecessary: only triglycerides genuinely respond to a meal, and that value falls outside the subtraction.

It is worth knowing that your cycle moves along with it. Cholesterol values fluctuate mildly with the oestradiol level, on the order of a few percent. That will not turn a result on its head, but anyone tracking the value over years does better to test at a comparable point in the cycle each time and to stay with the same laboratory.

Which question is worth asking depends above all on where you stand in your hormonal life course.

Do not test during or shortly after an acute illness, surgery or a heavy infection. Cholesterol values sink for weeks in such a period, so the result lands below your habitual level. A few weeks after recovery is early enough.

A single measurement also remains a snapshot. From day to day, total cholesterol and LDL fluctuate by some 5 to 10 percent, and triglycerides by 20 to 25 percent. A shift of 0.2 mmol/l between two results is therefore noise, and certainly not a trend.

If your non-HDL is unexpectedly high, look first for something underneath it before pointing at your diet. Thyroid conditions occur several times more often in women than in men, and an underactive thyroid raises LDL, so have your TSH run alongside. Disturbed blood sugar, kidney and liver conditions, cholestasis, heavy alcohol use and a range of medicines can all disturb a lipid profile as well. That belongs in a conversation with your doctor.